Skip to content
stoqly
en

Languages

Figures come from SEC filings, which are in English. Company and industry names stay as filed.

$ USD

Popular

All currencies

Data is in US dollars, converted at the ECB reference rate of Oct 23, 2026.

Replimune Group, Inc.

REPL Nasdaq Biological Products, (No Diagnostic Substances) Financials FY2017–FY2026

Download report 3-page PDF: the company, its results and charts with peers.

Last close Β· Oct 23, 2026

$11.46

4.4%

What Replimune Group, Inc. does

REPL Β· Biological Products, (No Diagnostic Substances)

From its latest annual report

No business description yet.

Filing details

Legal name
Replimune Group, Inc.
Fiscal year ends
March 31, 2026
Latest annual report
10-K Β· Jun 29, 2026
Accession Β· CIK
0001628280-26-045886 Β· 0001737953

KIRA’s summary AI analyst

Hi! I read Replimune Group, Inc.’s latest annual report (fiscal 2026). Here is what stands out:

1 strength 3 to watch

Replimune Group, Inc. in 30 seconds

Good So-so Weak

Weak

Does it make a profit?

βˆ’$314M

No. It lost money last year.

Weak

How healthy are the accounts?

1 / 7

Weak. It passes 1 of 7 health tests.

For information

How is the share priced?

β€”

No P/E: it made no profit over the last four quarters.

Rules of thumb on reported numbers. A starting point, not a recommendation.

Key numbers, fiscal 2026

Market cap Last close times the latest diluted share count, so it is approximate.
$1.1B
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
β€”
On βˆ’$3.15 EPS (TTM)

Revenue

Total sales reported in the income statement.

See the full section β†’

Operating margin

Operating income as a share of revenue.

See the full section β†’

Net income

Profit after all expenses, interest and tax.

KIRA Β· Replimune Group, Inc. lost $314M in fiscal 2026.

See the full section β†’

Free cash flow

Cash from operations minus capital spending.

KIRA Β· Free cash flow was βˆ’$285M in fiscal 2026, β€” of revenue.

See the full section β†’

Return on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

See the full section β†’
Charts by

Sales and profit

Is it selling more, and how much does it keep?

Results dates

In plain words: Every quarter, companies publish how much they sold and earned. These are the days Replimune Group, Inc. did it, and the next one. Share prices often move a lot on those days.

Next results

October 28, 2026

Wednesday Β· in 2 days

Time
Before the market opens
Covers
Period ended Sep 30, 2026
Expected EPS
βˆ’$0.70
Source
Earnings calendar
See who else reports that week β†’
Date Results for Time Source
Aug 14, 2026 Q1 '27 Before the market opens 8-K β†—
Jun 29, 2026 Q4 '26 Before the market opens 8-K β†—
Feb 3, 2026 Q3 '26 Before the market opens 8-K β†—
Nov 6, 2025 Q2 '26 Before the market opens 8-K β†—
Aug 7, 2025 Q1 '26 Before the market opens 8-K β†—
May 22, 2025 Q4 '25 Before the market opens 8-K β†—
Feb 12, 2025 Q3 '25 Before the market opens 8-K β†—
Nov 12, 2024 Q2 '25 Before the market opens 8-K β†—

From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.

Revenue and margins

In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).

Revenue

Margins, % of revenue

Gross Operating Net FCF

Net income and earnings per share

KIRA Β· Replimune Group, Inc. lost $314M in fiscal 2026.

Loss periods are shown in red.

In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.

Net income

Net income

Diluted EPS

Diluted EPS

Cash and shareholders

How much cash comes in, and where does it go?

Cash flow

KIRA Β· Free cash flow was βˆ’$285M in fiscal 2026, β€” of revenue.

Cash from operations minus capital spending.

In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.

Free cash flow

Free cash flow

Cash from operations vs capital spending

Cash from operations Capital spending

Cash from operations vs capital spending

Cash from operations Capital spending

Dividends, buybacks and share count

In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).

Dividends and buybacks

Dividends Buybacks

Diluted shares outstanding (annual)

Insider trades

KIRA Β· No open-market insider trades in the last 12 months.

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. β€œPlan” marks trades under a pre-arranged Rule 10b5-1 plan.

In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

β€”

$0.0M

No open-market insider trades in the last 12 months.

Financial health

Can it carry its debts, and how well does it use its money?

Balance sheet

KIRA Β· Replimune Group, Inc. has $161M more cash than debt.

Cash, debt and the ratios that show how comfortably Replimune Group, Inc. can carry it.

In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.

Cash vs debt (incl. leases)

Cash Debt
Fiscal year endFY22FY23FY24FY25FY26
Cash and short-term investments $396M$583M$421M$484M$269M
Debt incl. finance leases $27.0M$55.3M$70.9M$71.9M$108M
Debt / equity 0.0x0.1x0.1x0.1x0.5x
Interest coverage β€”βˆ’90.2xβˆ’52.2xβˆ’45.3xβˆ’47.1x
Current ratio 19.5x17.5x10.7x8.0x4.8x
Quick ratio 19.5x17.5x10.7x8.0x4.8x
Total assets $461M$647M$488M$551M$332M
Total liabilities $50.0M$91.3M$113M$135M$166M
Shareholders' equity $411M$555M$375M$416M$166M
Net debt (βˆ’ = net cash) βˆ’$369Mβˆ’$528Mβˆ’$350Mβˆ’$412Mβˆ’$161M

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.

Return on capital, equity and assets (annual)

Return on capital Return on equity Return on assets

Piotroski F-score

KIRA Β· Replimune Group, Inc. passes 1 of 7 financial health tests (Piotroski F-score).

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.

TestFY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Net income is positive βœ• βœ• βœ• βœ• βœ• βœ• βœ• βœ• βœ• βœ•
Cash from operations is positive βœ• βœ• βœ• βœ• βœ• βœ• βœ• βœ• βœ• βœ•
Return on assets rose β€” β€” βœ“ βœ• βœ“ βœ• βœ• βœ• βœ• βœ•
Cash from operations exceeds net income βœ“ βœ“ βœ“ βœ• βœ“ βœ“ βœ“ βœ“ βœ“ βœ“
Debt fell relative to assets β€” β€” β€” β€” β€” β€” βœ• βœ• βœ“ βœ•
Current ratio rose β€” β€” βœ“ βœ“ βœ“ βœ• βœ• βœ• βœ• βœ•
Share count didn't rise β€” βœ• βœ• βœ• βœ• βœ• βœ• βœ• βœ• βœ•
Gross margin rose β€” β€” β€” β€” β€” β€” β€” β€” β€” β€”
Revenue rose relative to assets β€” β€” β€” β€” β€” β€” β€” β€” β€” β€”
F-score β€” / 3β€” / 4β€” / 6β€” / 6β€” / 6β€” / 61 / 71 / 72 / 71 / 7
Accruals ratio β€”βˆ’5.7%βˆ’5.0%4.1%βˆ’5.0%βˆ’7.1%βˆ’8.3%βˆ’5.3%βˆ’10.6%βˆ’7.6%
Altman Z'' β€”βˆ’1.7311.755.2015.3210.177.770.84βˆ’0.42βˆ’13.44

All figures

Every number, year by year.

10 years of figures

Amounts in USD. Hover a ratio’s name for its definition.

In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.

Download CSV
Fiscal yearFY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Income statement
Research and development $6.9M $13.5M $22.2M $38.8M $56.8M $79.5M $127M $175M $189M $221M
Operating income βˆ’$9.6M βˆ’$19.2M βˆ’$30.9M βˆ’$56.2M βˆ’$80.0M βˆ’$118M βˆ’$177M βˆ’$235M βˆ’$262M βˆ’$320M
Interest expense β€” β€” β€” $0.7M $0.8M $0.0M $2.0M $4.5M $5.8M $6.8M
Pretax income βˆ’$7.7M βˆ’$19.7M βˆ’$30.8M βˆ’$52.6M βˆ’$80.9M βˆ’$118M βˆ’$174M βˆ’$215M βˆ’$247M βˆ’$314M
Income tax $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.3M $0.4M $0.5M βˆ’$0.6M
Net income βˆ’$7.7M βˆ’$19.7M βˆ’$30.8M βˆ’$52.6M βˆ’$80.9M βˆ’$118M βˆ’$174M βˆ’$216M βˆ’$247M βˆ’$314M
Net income to common βˆ’$7.7M βˆ’$19.7M βˆ’$30.8M βˆ’$52.6M βˆ’$80.9M βˆ’$118M βˆ’$174M βˆ’$216M βˆ’$247M βˆ’$314M
Diluted EPS βˆ’$1.55 βˆ’$3.96 βˆ’$1.33 βˆ’$1.54 βˆ’$1.75 βˆ’$2.26 βˆ’$2.99 βˆ’$3.24 βˆ’$3.07 βˆ’$3.38
Diluted shares 0.00B 0.00B 0.02B 0.03B 0.05B 0.05B 0.06B 0.07B 0.08B 0.09B
Cash flow
Cash from operations βˆ’$7.1M βˆ’$16.0M βˆ’$25.4M βˆ’$60.6M βˆ’$61.4M βˆ’$82.2M βˆ’$128M βˆ’$185M βˆ’$192M βˆ’$280M
Capital expenditure $0.2M $0.1M $2.6M $6.5M $2.4M $2.3M $2.3M $5.7M $6.7M $4.2M
Free cash flow βˆ’$7.3M βˆ’$16.2M βˆ’$28.0M βˆ’$67.1M βˆ’$63.8M βˆ’$84.5M βˆ’$130M βˆ’$191M βˆ’$199M βˆ’$285M
Depreciation and amortization $0.1M $0.1M $0.1M $0.5M $1.7M $2.1M $2.4M $2.7M $3.5M $3.3M
Stock-based compensation $0.2M $0.8M $2.7M $7.7M $11.8M $24.3M $28.1M $34.1M $35.0M $32.3M
Balance sheet
Cash and short-term investments $20.7M $61.6M $135M $169M $476M $396M $583M $421M $484M $269M
Total debt β€” β€” β€” $9.8M β€” $0.0M $28.6M $44.8M $46.4M $83.3M
Finance lease liabilities β€” β€” β€” $27.4M $27.2M $27.0M $26.6M $26.1M $25.5M $24.8M
Current assets β€” $64.7M $141M $174M $484M $404M $593M $434M $496M $279M
Current liabilities β€” $5.2M $9.9M $11.9M $14.5M $20.8M $33.8M $40.4M $62.4M $58.2M
Property and equipment, net β€” $0.4M $12.2M $6.9M $7.4M $7.9M $7.5M $10.5M $13.7M $13.0M
Total assets β€” $65.2M $154M $234M $543M $461M $647M $488M $551M $332M
Total liabilities β€” $6.9M $16.5M $50.4M $44.4M $50.0M $91.3M $113M $135M $166M
Shareholders' equity βˆ’$11.5M βˆ’$28.1M $138M $184M $499M $411M $555M $375M $416M $166M
Returns
Return on capital β€” β€” β€” βˆ’177.8% β€” βˆ’600.2% βˆ’25,251.5% β€” β€” β€”
Return on capital employed β€” βˆ’32.1% βˆ’21.4% βˆ’25.3% βˆ’15.1% βˆ’26.9% βˆ’28.9% βˆ’52.5% βˆ’53.5% βˆ’116.7%
Return on equity β€” β€” βˆ’56.2% βˆ’32.7% βˆ’23.7% βˆ’25.9% βˆ’36.1% βˆ’46.4% βˆ’62.6% βˆ’107.9%
Return on assets β€” βˆ’30.2% βˆ’28.1% βˆ’27.1% βˆ’20.8% βˆ’23.5% βˆ’31.5% βˆ’38.0% βˆ’47.6% βˆ’71.1%
Return on tangible equity β€” β€” βˆ’22.4% βˆ’28.6% βˆ’16.2% βˆ’28.7% βˆ’31.4% βˆ’57.6% βˆ’59.5% βˆ’188.9%
Growth
Share count change β€” 0.1% 366.0% 47.7% 35.0% 12.9% 11.5% 14.4% 21.0% 15.2%
Financial health
Debt / equity β€” β€” β€” 0.1x β€” 0.0x 0.1x 0.1x 0.1x 0.5x
Interest coverage β€” β€” β€” βˆ’76.6x βˆ’97.7x β€” βˆ’90.2x βˆ’52.2x βˆ’45.3x βˆ’47.1x
Current ratio β€” 12.5x 14.3x 14.7x 33.3x 19.5x 17.5x 10.7x 8.0x 4.8x
Quick ratio β€” 12.5x 14.3x 14.7x 33.3x 19.5x 17.5x 10.7x 8.0x 4.8x
Quality scores
Piotroski F-score β€” β€” β€” β€” β€” β€” 1.0 1.0 2.0 1.0
Altman Z'' β€” βˆ’1.7 11.8 5.2 15.3 10.2 7.8 0.8 βˆ’0.4 βˆ’13.4
Accruals ratio β€” βˆ’5.7% βˆ’5.0% 4.1% βˆ’5.0% βˆ’7.1% βˆ’8.3% βˆ’5.3% βˆ’10.6% βˆ’7.6%

Source: SEC EDGAR XBRL filings (CIK 0001737953). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β€” not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move Β· ↡ to open